SCHEMBL21595576

SCHEMBL21595576

O=C(Nc1ccccc1F)c1ccc(OC(F)F)cn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.56
NPC1 O15118 4/20 0.56
P4HTM Q9NXG6 1/20 0.55
KMT2A Q03164 3/20 0.52
TNKS O95271 1/20 0.48
TNKS2 Q9H2K2 1/20 0.48
RAB9A P51151 6/20 0.47
CASP3 P42574 1/20 0.47
TAAR1 Q96RJ0 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
GRM4 Q14833 1/20 0.47
BACE1 P56817 4/20 0.47
GAA P10253 1/20 0.45
HTT P42858 1/20 0.45
MEN1 O00255 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
GSK3A P49840 1/20 0.44
GSK3B P49841 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30763098 1.00 SMN1; SMN2 (0.56) SMN1; SMN2NPC1P4HTMKMT2ATNKS
SCHEMBL30763161 0.88 SMN1; SMN2 (0.59) SMN1; SMN2NPC1P4HTMKMT2ATNKS2
SCHEMBL21595573 0.88 SMN1; SMN2 (0.59) SMN1; SMN2NPC1P4HTMKMT2ATNKS2
SCHEMBL21595584 0.86 KMT2A (0.45) SMN1; SMN2NPC1P4HTMKMT2ATNKS
SCHEMBL30763060 0.86 KMT2A (0.45) SMN1; SMN2NPC1P4HTMKMT2ATNKS
SCHEMBL21595582 0.82 SMN1; SMN2 (0.60) SMN1; SMN2NPC1P4HTMKMT2ARAB9A
SCHEMBL30763190 0.82 SMN1; SMN2 (0.60) SMN1; SMN2NPC1P4HTMKMT2ARAB9A
SCHEMBL21595594 0.81 SMN1; SMN2 (0.59) SMN1; SMN2NPC1P4HTMKMT2ARAB9A
SCHEMBL21595580 0.80 SMN1; SMN2 (0.57) SMN1; SMN2NPC1P4HTMKMT2ATNKS2
SCHEMBL21096166 0.78 KMT2A (0.56) SMN1; SMN2NPC1P4HTMKMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3810597-B1 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS UNIV OSLO HF (NO) 2025-11-26 EP disclosed
US-11926614-B2 1,2,4-triazole derivatives as tankyrase inhibitors OSLO UNIVERSITETSSYKEHUS HF (NO) 2024-03-12 US disclosed
EP-3810597-A1 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS Oslo Universitetssykehus HF (NO) 2021-04-28 EP disclosed
WO-2019243822-A1 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS OSLO UNIVERSITETSSYKEHUS HF (NO) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11926614-B2 1,2,4-triazole derivatives as tankyrase inhibitors GBA3, CBR3, TECR SMN1; SMN2 4006/4885NPC1 1998/4885P4HTM 1349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.